November 09, 2022
Article
At AHA 2022, Dr. Ray discusses the findings from the phase II open-label extension trial and highlights other important trial data for lipidologists.
A pair of studies leveraging NIS data detail the risk of cardiovascular complications during delivery admissions among pregnant persons with a history of systemic lupus erythematosus or use of assisted reproductive technologies relative to their counterparts who did not.
November 08, 2022
Video
A deep dive into exciting late-breaking trial data at AHA 2022, differences in chest pain guidelines, and bringing patient voice into clinical research.
Ridker joins to discuss some of his recent work, provide a deep dive into use of inflammatory biomarkers for identifying patients with residual inflammatory risk, provide perspective on use of MACE compared with all-cause mortality in cardiovascular clinical trials, and discuss the optimized uptake of SGLT2 inhibitors in care.
A Q&A with Dr. Bonaca highlights new data on rivaroxaban for PAD and the late-breaking science at AHA 2022.
November 07, 2022
In this episode of The Heart Team, which was recorded on-site at AHA 2022, Scott Solomon, MD, takes hosts Jorge Plutzky, MD, and Michael Farkouh, MD, on a deep dive into his experience as a trialist, use of newer medications, and what might be next for the heart failure community.
The trial achieved its primary efficacy endpoint of terminating PSVT with self-administered etripamil, using symptom-based optional repeat dosing.
Following a session examining the application of the latest iterations of cardiometabolic health guidelines, Diana Isaacs, PharmD, discusses how the evolving role of diabetes, and recognition of this role, in cardiovascular disease is reflected at the American Heart Association 2022 Scientific Sessions.
November 06, 2022
Results of the CTS-AMI study presented at AHA 22 suggests tongxiluo, which is an herbal medicine compound used in China, could reduce risk of cardiac events and mortality following a heart attack.
November 05, 2022
A substudy of the PRO-HF study indicates incorporation of KCCQ-12 scores was associated with an improved patient experience and a greater understanding of symptoms.
Heather Woolery-Lloyd, MD, FAAD: Interview on Common Skin of Color Dermatoses
Orit Markowitz, MD: Artificial Intelligence, Patient Knowledge on Skin Cancer
Ruxolitinib Cream Improves Atopic Dermatitis Pain, Anxiety and Depression Over 52 Weeks
